Global lead investigator, TALAPRO-3
Appears in 1 story
Last updated Oct 29, 2026
Presented the final results at ASCO 2026
The Food and Drug Administration approved talazoparib (Talzenna) plus enzalutamide (Xtandi) on October 26 for men whose metastatic prostate cancer carries mutations in DNA-repair genes and who have not yet started hormone therapy for castration-resistant disease. The clearance moves the pair into the earlier castration-sensitive stage, where the trial showed it cut the risk of the cancer spreading or the patient dying by 52%.
Updated Oct 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
